Dexamethasone protects against cisplatin-induced activation of the mitochondrial apoptotic pathway in human osteosarcoma cells

Stefan Meyer, Tim Eden, Helen Kalirai

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Background: Dexamethasone (Dx) is often used to alleviate the acute emetic toxicity associated with high dose cisplatin (cDDP) in osteosarcoma patients. However, in other tumour cell types, Dx has been reported to induce partial resistance to anticancer drugs. Materials and Methods: We examined the effect of Dx on cDDP-induced apoptosis in the HOS human osteosarcoma cell line. Results: Exposure to cDDP, induced apoptosis via the mitochondrial apoptotic pathway as evidenced by cytochrome c release and caspase activation. Pre and cotreatment of HOS cells with Dx reduced cDDP induced apoptosis by 10-25%. Investigation of the mechanisms of this protective effect indicated both the upregulation of the survival factor Akt and a possible direct receptor-mediated action of Dx to attenuate the activation of the mitochondrial apoptotic pathway components. Conclusions: These data indicate the need to carefully address the timing of glucocorticoid use in the clinical management of cancer patients. ©2006 Landes Bioscience.
    Original languageEnglish
    Pages (from-to)915-920
    Number of pages5
    JournalCancer Biology and Therapy
    Volume5
    Issue number8
    DOIs
    Publication statusPublished - Aug 2006

    Keywords

    • Apoptosis
    • Cisplatin
    • Glucocorticoid
    • Mitochondria
    • Osteosarcoma

    Fingerprint

    Dive into the research topics of 'Dexamethasone protects against cisplatin-induced activation of the mitochondrial apoptotic pathway in human osteosarcoma cells'. Together they form a unique fingerprint.

    Cite this